0000899243-16-028321.txt : 20160831
0000899243-16-028321.hdr.sgml : 20160831
20160831204747
ACCESSION NUMBER: 0000899243-16-028321
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160425
FILED AS OF DATE: 20160831
DATE AS OF CHANGE: 20160831
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aunins John G.
CENTRAL INDEX KEY: 0001643756
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 161864399
MAIL ADDRESS:
STREET 1: C/O SERES HEALTH, INC.
STREET 2: 161 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02472
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2016-04-25
2016-04-27
0
0001609809
Seres Therapeutics, Inc.
MCRB
0001643756
Aunins John G.
C/O SERES THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Technology Officer & EVP
Common Stock
2016-04-25
4
S
0
18640
31.94
D
56060
D
This line item is not new or revised, but is being reported again solely to gain access to the electronic filing system for filing this amendment. This Form 4 when it was initially filed by the Reporting Person on April 27, 2016 and four Forms 4 filed by the Reporting Person after that date incorrectly stated the date the Reporting Person adopted his 10b5-1 trading plan. This amendment is being filed to correct such date.
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2016.
The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $31.48 to $32.34. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Thomas J. DesRosier, Attorney-in-fact
2016-08-31